Skip to main content
SpringerLink
Log in

Gimeracil/oteracil/tegafur/rivoceranib

Small bowel obstruction: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ding K, et al. Gastric cancer harboring an erbb3 mutation treated with a pyrotinib-irinotecan combo: A case study. OncoTargets and Therapy 14: 545-550, Jan 2021. Available from: URL: http://doi.org/10.2147/OTT.S286024

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gimeracil/oteracil/tegafur/rivoceranib. Reactions Weekly 1843, 170 (2021). https://doi.org/10.1007/s40278-021-91272-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-91272-y

Search

Navigation